Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 12, 2022
Daily News
September 12, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
- Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…